Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887934 | 0.84 | MAOB (0.69) | EGLN1MAOBRAB9ANPC1HIF1A | |
| SCHEMBL18667425 | 0.84 | MEN1 (0.52) | EGLN1MAOBMEN1KMT2ACNR1 | |
| SCHEMBL280282 | 0.83 | EGLN1 (0.57) | EGLN1MAOBRAB9A | |
| SCHEMBL10228354 | 0.81 | CNR1 (0.57) | EGLN1MAOBMEN1KMT2ACNR1 | |
| SCHEMBL31500499 | 0.81 | L3MBTL1 (0.59) | EGLN1MAOBMEN1KMT2ACNR1 | |
| SCHEMBL14124612 | 0.80 | SMN1; SMN2 (0.53) | EGLN1MAOBMEN1KMT2ACNR1 | |
| SCHEMBL14395788 | 0.80 | LMNA (0.57) | EGLN1MAOBMEN1KMT2ACNR1 | |
| SCHEMBL827894 | 0.79 | CNR1 (0.54) | EGLN1MEN1KMT2ACNR1RAB9A | |
| SCHEMBL107387 | 0.78 | P2RX7 (0.53) | EGLN1MAOBMEN1KMT2ARAB9A | |
| SCHEMBL17298863 | 0.76 | EGLN1 (0.50) | EGLN1MAOBCNR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2023-01-19 | — | — | US | disclosed |
| WO-2021099793-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | CPN1, CMBL, ALDH7A1 | EGLN1 1490/4885MAOB 294/4885MEN1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.